Skip Navigation


Rheumatology Advance Access originally published online on October 17, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/1/39    most recent
keg459v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gong, J.-H.
Right arrow Articles by Clark-Lewis, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gong, J.-H.
Right arrow Articles by Clark-Lewis, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2004; 43: 39-42
© British Society for Rheumatology 2003

Basic Science

Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy

J.-H. Gong, R. Yan1, J. D. Waterfield1 and I. Clark-Lewis{dagger}

Biomedical Research Centre and Department of Biochemistry and Molecular Biology, and 1Department of Oral Biological and Medical Sciences, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence to: J. D. Waterfield, Faculty of Dentistry, 2199 Wesbrook Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Abstract

Objective. To investigate the effect of targeting the chemotaxis of monocytes and polymorphonuclear monocytes (PMNs) in situ in MRL-Faslpr arthritis.

Methods. MRL-Faslpr mice were injected intradermally with complete Freund's adjuvant and cellular infiltration into the joint was monitored. Once clinical disease developed, the animals received one of three treatments: MCP-1(9–76); MCP-1(9–76) plus Gro-{alpha}(8–73); or control peptide, MCP-1 Ala. The bimalleolar ankle width was measured for 11 days and histological examination of the joints was then assessed.

Results. Cellular infiltration started after the onset of ankle swelling, and increased progressively. The incidence of swelling and the histopathology was reduced after day 6 of treatment in the MCP-1(9–76)-treated mice. Mice treated with the two antagonists MCP-1(9–76) and Gro-{alpha}(8–73) displayed a further significant reduction in disease parameters.

Conclusion. Treatment after disease onset with chemotactic antagonists for monocytes and PMNs significantly alleviated both the swelling and the histopathology seen in arthritis, suggesting that chemokine antagonists are an effective anti-inflammatory therapy.

KEY WORDS: Arthritis, Chemokines, Antagonists

Notes

{dagger}This paper is dedicated to Dr I. Clark-Lewis, whose untimely death has saddened his many friends and collaborators in the scientific community.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Shahrara, A. E. I. Proudfoot, C. C. Park, M. V. Volin, G. K. Haines, J. M. Woods, C. H. Aikens, T. M. Handel, and R. M. Pope
Inhibition of Monocyte Chemoattractant Protein-1 Ameliorates Rat Adjuvant-Induced Arthritis
J. Immunol., March 1, 2008; 180(5): 3447 - 3456.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.